Immunocore Holdings plc Increase (Decrease) in Accounts Receivable
Immunocore Holdings plc (IMCR) reported Increase (Decrease) in Accounts Receivable of $22.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Immunocore Holdings plc increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $14.62M, a 250.04% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $7.93M.
- Immunocore Holdings plc increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$1.99M, a 253.98% decline year-over-year.
- Immunocore Holdings plc increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $5.99M, a 173.22% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in accounts receivable for fiscal 2025 was $7.34M, a 40.59% decline from fiscal 2024.
- Immunocore Holdings plc increase (decrease) in accounts receivable for fiscal 2024 was $12.35M, a 30.90% decline from fiscal 2023.
- Immunocore Holdings plc increase (decrease) in accounts receivable for fiscal 2023 was $17.87M, a 31.96% decline from fiscal 2022.
- Immunocore Holdings plc increase (decrease) in accounts receivable for fiscal 2022 was $26.26M, a 440.08% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.55M 10-Q · filed 2026-08-06 | $20.56M derived: sum of 3 quarters · filed 2026-08-06 | $26.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.93M 10-Q · filed 2026-05-06 | $5.94M derived: sum of 2 quarters · filed 2026-05-06 | $11.93M derived: sum of 3 quarters · filed 2026-05-06 | $16.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.00M derived: sum of 2 quarters · filed 2026-02-25 | $8.17M derived: sum of 3 quarters · filed 2026-08-06 | $7.34M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.17M derived: sum of 2 quarters · filed 2026-08-06 | $9.33M 10-Q · filed 2025-11-06 | $10.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.34M 10-Q · filed 2026-08-06 | $4.64M derived: sum of 3 quarters · filed 2026-08-06 | $6.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$836.00K 10-Q · filed 2026-05-06 | $459.00K derived: sum of 2 quarters · filed 2026-05-06 | $2.65M derived: sum of 3 quarters · filed 2026-05-06 | $5.31M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.49M derived: sum of 2 quarters · filed 2026-02-25 | $6.15M derived: sum of 3 quarters · filed 2026-02-25 | $12.35M 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.86M derived: sum of 2 quarters · filed 2025-11-06 | $11.05M 10-Q · filed 2025-11-06 | $21.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.86M 10-Q · filed 2025-08-07 | $19.09M derived: sum of 3 quarters · filed 2026-02-25 | $19.56M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $6.20M 10-Q · filed 2025-05-07 | $16.42M derived: sum of 2 quarters · filed 2026-02-25 | $16.89M derived: sum of 3 quarters · filed 2026-02-25 | $20.49M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.70M derived: sum of 2 quarters · filed 2026-02-25 | $14.29M derived: sum of 3 quarters · filed 2026-02-25 | $17.87M 10-K · filed 2026-02-25 |
| 2023-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.07M derived: sum of 2 quarters · filed 2024-11-06 | $7.65M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.18M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $3.58M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $26.26M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $4.86M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |